vs

Side-by-side financial comparison of First Bancorp, Inc (FNLC) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $25.8M, roughly 1.5× First Bancorp, Inc). First Bancorp, Inc runs the higher net margin — 39.4% vs -161.8%, a 201.2% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 17.5%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-71.3M).

Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

FNLC vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.5× larger
IBRX
$38.3M
$25.8M
FNLC
Growing faster (revenue YoY)
IBRX
IBRX
+389.4% gap
IBRX
407.0%
17.5%
FNLC
Higher net margin
FNLC
FNLC
201.2% more per $
FNLC
39.4%
-161.8%
IBRX
More free cash flow
FNLC
FNLC
$105.9M more FCF
FNLC
$34.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FNLC
FNLC
IBRX
IBRX
Revenue
$25.8M
$38.3M
Net Profit
$10.2M
$-61.9M
Gross Margin
99.0%
Operating Margin
48.1%
-169.0%
Net Margin
39.4%
-161.8%
Revenue YoY
17.5%
407.0%
Net Profit YoY
39.7%
-4.7%
EPS (diluted)
$0.91
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FNLC
FNLC
IBRX
IBRX
Q4 25
$25.8M
$38.3M
Q3 25
$24.5M
$32.1M
Q2 25
$22.5M
$26.4M
Q1 25
$21.8M
$16.5M
Q4 24
$22.0M
$7.6M
Q3 24
$20.5M
$6.1M
Q2 24
$19.2M
Q1 24
$18.5M
Net Profit
FNLC
FNLC
IBRX
IBRX
Q4 25
$10.2M
$-61.9M
Q3 25
$9.1M
$-67.3M
Q2 25
$8.1M
$-92.6M
Q1 25
$7.1M
$-129.6M
Q4 24
$7.3M
$-59.2M
Q3 24
$7.6M
$-85.7M
Q2 24
$6.2M
Q1 24
$6.0M
Gross Margin
FNLC
FNLC
IBRX
IBRX
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
FNLC
FNLC
IBRX
IBRX
Q4 25
48.1%
-169.0%
Q3 25
45.2%
-173.5%
Q2 25
43.7%
-269.8%
Q1 25
39.3%
-390.1%
Q4 24
39.5%
-919.0%
Q3 24
44.6%
-1314.3%
Q2 24
38.8%
Q1 24
39.3%
Net Margin
FNLC
FNLC
IBRX
IBRX
Q4 25
39.4%
-161.8%
Q3 25
37.0%
-209.8%
Q2 25
35.8%
-350.3%
Q1 25
32.5%
-784.9%
Q4 24
33.1%
-783.4%
Q3 24
36.9%
-1404.0%
Q2 24
32.1%
Q1 24
32.5%
EPS (diluted)
FNLC
FNLC
IBRX
IBRX
Q4 25
$0.91
$-0.06
Q3 25
$0.81
$-0.07
Q2 25
$0.72
$-0.10
Q1 25
$0.63
$-0.15
Q4 24
$0.66
$-0.08
Q3 24
$0.68
$-0.14
Q2 24
$0.55
Q1 24
$0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FNLC
FNLC
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
$95.5M
Stockholders' EquityBook value
$283.1M
$-500.5M
Total Assets
$3.2B
$501.9M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FNLC
FNLC
IBRX
IBRX
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Q1 24
Total Debt
FNLC
FNLC
IBRX
IBRX
Q4 25
$95.5M
Q3 25
$95.5M
Q2 25
$95.0M
Q1 25
$70.0M
Q4 24
$95.0M
Q3 24
$95.0M
Q2 24
$70.0M
Q1 24
$70.0M
Stockholders' Equity
FNLC
FNLC
IBRX
IBRX
Q4 25
$283.1M
$-500.5M
Q3 25
$274.6M
$-524.3M
Q2 25
$265.5M
$-570.7M
Q1 25
$259.7M
$-591.4M
Q4 24
$252.5M
$-489.1M
Q3 24
$256.8M
$-745.1M
Q2 24
$244.7M
Q1 24
$242.6M
Total Assets
FNLC
FNLC
IBRX
IBRX
Q4 25
$3.2B
$501.9M
Q3 25
$3.2B
$519.0M
Q2 25
$3.2B
$402.1M
Q1 25
$3.2B
$303.8M
Q4 24
$3.2B
$382.9M
Q3 24
$3.1B
$364.6M
Q2 24
$3.1B
Q1 24
$3.0B
Debt / Equity
FNLC
FNLC
IBRX
IBRX
Q4 25
0.34×
Q3 25
0.35×
Q2 25
0.36×
Q1 25
0.27×
Q4 24
0.38×
Q3 24
0.37×
Q2 24
0.29×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FNLC
FNLC
IBRX
IBRX
Operating Cash FlowLast quarter
$37.8M
$-70.4M
Free Cash FlowOCF − Capex
$34.6M
$-71.3M
FCF MarginFCF / Revenue
133.9%
-186.2%
Capex IntensityCapex / Revenue
12.5%
2.4%
Cash ConversionOCF / Net Profit
3.72×
TTM Free Cash FlowTrailing 4 quarters
$55.3M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FNLC
FNLC
IBRX
IBRX
Q4 25
$37.8M
$-70.4M
Q3 25
$12.9M
$-68.9M
Q2 25
$7.4M
$-79.7M
Q1 25
$2.2M
$-85.9M
Q4 24
$26.0M
$-85.1M
Q3 24
$9.8M
$-98.8M
Q2 24
$6.4M
Q1 24
$-1.5M
Free Cash Flow
FNLC
FNLC
IBRX
IBRX
Q4 25
$34.6M
$-71.3M
Q3 25
$12.6M
$-69.6M
Q2 25
$7.2M
$-80.8M
Q1 25
$828.0K
$-87.0M
Q4 24
$24.6M
$-87.3M
Q3 24
$9.6M
$-101.6M
Q2 24
$6.3M
Q1 24
$-1.8M
FCF Margin
FNLC
FNLC
IBRX
IBRX
Q4 25
133.9%
-186.2%
Q3 25
51.4%
-217.2%
Q2 25
32.1%
-305.9%
Q1 25
3.8%
-526.9%
Q4 24
111.7%
-1155.4%
Q3 24
47.0%
-1663.2%
Q2 24
32.9%
Q1 24
-9.8%
Capex Intensity
FNLC
FNLC
IBRX
IBRX
Q4 25
12.5%
2.4%
Q3 25
1.2%
2.3%
Q2 25
0.6%
4.1%
Q1 25
6.2%
6.8%
Q4 24
6.7%
28.0%
Q3 24
0.5%
45.7%
Q2 24
0.3%
Q1 24
1.8%
Cash Conversion
FNLC
FNLC
IBRX
IBRX
Q4 25
3.72×
Q3 25
1.42×
Q2 25
0.91×
Q1 25
0.31×
Q4 24
3.58×
Q3 24
1.29×
Q2 24
1.03×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons